SurrozenSRZN
Recorded

Surrozen Guggenheim 3rd Annual Healthcare Innovation Conference

Review the key takeaways and the transcript of this earnings call.

PeriodFY 0Duration27 minParticipants2

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Yatin SunejaSenior Managing Director And Biotechnology Analyst

Yatin Suneja from Guggenheim. My pleasure to Craig Parker, the CEO of Surrozen here. We will be chatting for the next, let's say, 25, 30 minutes. Craig, thank you so much. We always appreciate your presence, you coming, spending time with us. Why don't you make some opening comments? There were some key updates that you provided yesterday on the earnings release. Maybe recap that. Then obviously, we have a lot to discuss between your program and some of the stuff that is happening on the competitive dynamic. Why don't you make some comments?

Craig ParkerCEO

Yeah. It's a very exciting time for Wnt biology, exciting time for retina broadly, retinal vascular diseases broadly. The background of Surrozen is we actually started as a Wnt biology-focused company. We discovered the multifunctional antibodies that we've been pursuing, and have looked at a number of different areas and arrived at targeting the specific receptors that we're targeting, and that the Merck molecule targets, because of some really compelling human genetics, some childhood retinal diseases that illustrate how important these targets and this pathway are in preserving normal retinal vessel function.

Craig ParkerCEO

So, we made an antibody that we thought really accomplished a number of key objectives in treating the disease, and I think we'll talk about the Merck data, but the combination of the clinical benefit that's been shown with all the anti-VEGF molecules combined now with the clinical benefit that's been shown with targeting Wnt signaling, and we're activating Wnt signaling with that portion of the molecule, those really look like the two best mechanisms to treat retinal vascular diseases, at least diabetic macular edema.

Craig ParkerCEO

Got it. That's the foundation for our approach, was to take our knowledge of Wnt signaling, combine it with what's been proven to be very efficacious in these retinal vascular diseases into one molecule.

Yatin SunejaSenior Managing Director And Biotechnology Analyst

Got it. I think it'll be helpful to put in perspective on what is going on in that space. Obviously, at the AAO, Merck's BRUNELLO data got presented. There was a lot of focus going into it. What were the key learnings for you? Maybe put in perspective the efficacy and both the safety and the efficacy profile that we saw with the Merck molecule.

Craig ParkerCEO

Yeah. This was a large phase III, nearly 1,000-patient phase III trial. Patients had diabetic macular edema. About three-quarters of them were treatment-naive diabetic macular edema patients. In the study, they got randomized to either LUCENTIS, which is one of the older- Yeah VEGF antibody fragments, or one of two doses of what's now called remigromig.

Craig ParkerCEO

People will also know it as MK-3000 or Restoret. This is their Frizzled 4/LRP5-targeted Wnt agonist. Really, for the first time ever with something other than a VEGF mechanism, what they showed was you can get VEGF-like efficacy, and that's measured in a couple of ways that I'll come back to. So, VEGF-like efficacy. That really alone is quite a breakthrough for the field, that a non-VEGF mechanism could show this kind of clinical benefit. Others have been tried alone, like Ang-2 alone, IL-6 alone. None of these have shown that magnitude of benefit. On the safety side, other than something called proliferative diabetic retinopathy, where they saw higher rates, it was very safe, so no other intraocular inflammation. I think that's really important for the field.

Craig ParkerCEO

Some other aspects of the data that I think were very important, visual acuity was correlated with drying, and that's something we did not know with Wnt signaling, whether those would be as well correlated as they are with anti-VEGF therapy. The onset of clinical benefit was very rapid. It was as rapid as VEGF. That's something else we didn't know about Wnt signaling, that it could result in very rapid retinal drying.

Craig ParkerCEO

Yeah. That's really encouraging for us.

Craig ParkerCEO

Then we have an anti-VEGF component to our molecule.

Craig ParkerCEO

Yeah. The way you treat proliferative diabetic retinopathy and vitreous hemorrhage, which is what they saw, is with anti-VEGF molecules.

Craig ParkerCEO

When we left the, literally walked out of the theater where the data was presented, we happened to talk to a couple of our clinical advisors. You can see who they are on our website. They all said, "This is the perfect landscape for you. Wnt works really well. Yeah.

Craig ParkerCEO

Part of your molecule is going to treat the one potential liability of the Merck molecule, which is proliferative diabetic retinopathy.

Yatin SunejaSenior Managing Director And Biotechnology Analyst

Got it. With regard to, again, going into the study, there were two focuses, right? Or the two or three things people were focused on. One was obviously on the safety side. On the PDR adverse rate, do you get a sense that that has been put to, or that is behind us now? People are not really focusing on. Is it more of a- Yeah.

Yatin SunejaSenior Managing Director And Biotechnology Analyst

Maybe talk about that. Sure.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day